DOCSLIB.ORG

Forum for Innovative Regenerative Medicine Members

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Forum for Innovative Regenerative Medicine Members Forum for Innovative Regenerative Medicine Ｍｅｍｂｅｒｓ As of May 1, 2021 Chairman Ken-ichiro Hata Japan Tissue Engineering Co., Ltd. Vice-chairmen Yoshitsugu Shitaka Astellas Pharma Inc. Nobuyuki Osakabe Hitachi, Ltd. Kunihiko Suzuki MEDINET Co., Ltd. Directors Mikitomo Yasutake Asahi Kasei Corporation Setsuko Hashimoto CellSeed Inc. Masayuki Yabuta Daiichi Sankyo Co., Ltd. Toshiki Sugimoto Dai Nippon Printing Co., Ltd. Junji Okada FUJIFILM Corporation iPS PORTAL, Inc. Tatsuo Suzuki JCR Pharmaceuticals Co., Ltd. Yoshifumi Torii Kyowa Kirin Co., Ltd. Tohru Hirose Novartis Pharma K.K. Osamu Takahashi PHC Corporation Kazuya Omi SRL, Inc. Toru Kimura Sumitomo Dainippon Pharma Co., Ltd. Masanobu Kimura TAKARA BIO INC. Yasushi Kajii Takeda Pharmaceutical Company Limited Kazuhisa Senshu TERUMO CORPORATION Supervisory Mitsuomi Shirahashi iPS Academia Japan, Inc. Board Members Hironao Yazaki ERNST & YOUNG SHINNIHON LLC Regular Members Regular Members ADEKA CORPORATION Hitachi, Ltd. Advantec kensyusenta HITACHIZOSEN CORPORATION AGC Inc. Hyperion Drug Discovery Co., Ltd Airex Co.,Ltd. iHeart Japan Corporation AIRTECH JAPAN, LTD. IKARI SHODOKU CO.,LTD. AJINOMOTO CO., INC. Ikeda Scientific, Co., Ltd. Alfresa Holdings Corporation iPS Academia Japan, Inc. Anderson Mori & Tomotsune iPS PORTAL, Inc. AnGes, Inc. Ipsos Healthcare Japan Limited Asahi Kasei Corporation IQVIA Services Japan K.K. Astellas Pharma Inc. Iwatani Corporation bioMerieux Japan Ltd. Janssen Pharmaceutical K.K. BIOMIMETICS SYMPATHIES Inc. Japan Tissue Engineering Co., Ltd. BrightPath Biotherapeutics Co., Ltd. JCR Pharmaceuticals Co., Ltd. Celgene K.K. JMS CO,.LTD Cell Exosome Therapeutics JSR Corporation Cell Science & Technology Institute Inc. JTEC CORPORATION CellBank Corp. JUNTEN BIO Co.,Ltd. CellGenTech, Inc. Kaken Pharmaceutical Co., Ltd. CellSeed Inc. KANEKA CORPORATION CellSource Co., Ltd. KANTO CHEMICAL CO., INC. CHIYODA CORPORATION Kirin Holdings Company, Limited chromocenter Inc. Kohjin Bio Co., Ltd. Chugai Pharmaceutical Co., Ltd. KOKEN CO., LTD. CMIC Co., Ltd. KYOCERA Corporation CPC Corporation Kyokuto Pharmaceutical Industrial Co., Ltd. Cuorips Inc. KYORIN Pharmaceutical Co., Ltd. Cyfuse Biomedical K.K. Kyowa Kirin Co., Ltd. Dai Nippon Printing Co., Ltd. Life Science Institute, Inc. DAI-DAN CO,.LTD. Life Technologies Japan K.K. Daiichi Sankyo Co., Ltd. Lonza Japan Ltd. Denka Co., Ltd. Lymphocyte-bank Co.,Ltd. Earth Environmental Service Co., Ltd. Macrobiosis Inc. Eil Inc. MARUBISHI BIOENGINEERING Co., Ltd. EPS Corporation Maruho Co., Ltd. ESPEC CORP. MATRIXOME, Inc. FUJIFILM Corporation MEDINET Co., Ltd. FUJIFILM Wako Pure Chemical Corporation MEDIPAL HOLDINGS CORPORATION FUJISOFT INCORPORATED Megakaryon Corporation FUKOKU CO., LTD. Merck Ltd. Funakoshi Co.,Ltd. Metcela Inc. Gene Techno Science Co.,Ltd. METRAS, Inc. Grandsoul Research Institute for Immunology, Inc. MICRON Inc. HEALIOS K.K. micronix Co., Ltd. Heartseed Inc. Mitsubishi Chemical Corporation 1 Forum for Innovative Regenerative Medicine Ｍｅｍｂｅｒｓ As of May 1, 2021 Regular Members Regular Members MITSUBISHI GAS CHEMICAL COMPANY,INC. Saraya Co., Ltd. MITSUBISHI LOGISTICS CORPORATION SAROUTE Co., Ltd. Mitsui Fudosan Co., Ltd. Sartorius Stedim Japan K.K. Mitsui-soko Holdings Co., Ltd. SD Biosystem Co.,Ltd. MIURA CO.,LTD Seed Planning, Inc. MOCHIDA PHARMACEUTICAL CO., LTD. SEIKEN CO.,LTD. Myoridge Co. Ltd. SHIBAMATA TRANSPORT Co.,Ltd. NanoCarrier Co.,Ltd. SHIBUYA KOGYO CO., LTD. Nard institute, LTD. Shimadzu Corporation Nexredge Inc. SHIMIZU CORPORATION NICHIREI BIOSCIENCES INC. Shin Nippon Biomedical Laboratories, Ltd. （SNBL) NIHON KOHDEN CORPORATION Shiseido Company, Limited NIKON CORPORATION Showa Denko Materials Co., Ltd. Nippi, Incorporated SMC Corporation Nippon Express Co.,Ltd. Sompo Japan Nipponkoa Insurance Inc. NIPRO CORPORATION SRD Co., Ltd. Nissan Chemical Corporation SRL, Inc. NISSIN CORPORATION Sumitomo Bakelite Co., Ltd. NISSUI PHARMACEUTICAL CO., LTD. SUMITOMO CHEMICAL Co., Ltd. NITTA Corporation Sumitomo Dainippon Pharma Co., Ltd. NOK Co. SUZUKEN CO., LTD. North American Science Associates Japan G.K. SYSMEX CORPORATION Novartis Pharma K.K. TAIYO NIPPON SANSO Corporation NSK Ltd. TAKARA BIO INC. Optima Inc. Takeda Pharmaceutical Company Limited Osaka Sanitary Co.,Ltd. Takenaka Corporation Otsuka Pharmaceutical Co., Ltd. Teijin Limited Otsuka Pharmaceutical Factory, Inc. TEIJIN PHARMA LIMITED Panasonic Environmental Systems & Engineering Co., Ltd. Tella Pharma Inc. PERSOL TEMPSTAFF CO.,LTD. TERUMO CORPORATION Pfizer Japan Inc. Tokio Marine & Nichido Fire Insurance Co., Ltd. Pharma Solutions Co., Ltd. TOMITA PHARMACEUTICAL CO.,LTD. PharmaBio Corporation TOPPAN PRINTING CO., LTD. PHC Corporation TOSOH CORPORATION RAYMEI INC. Toyo Seikan Group Holdings, Ltd. ReproCELL Inc. Trust Express Co., Ltd. RION CO., LTD. ＵｎｉＢｉｏ Ｃｏｒｐｏｒａｔｉｏｎ Roche Diagnostics K.K. Vision Care Inc. ROHTO Pharmaceutical Co., Ltd. VITAL KSK HOLDINGS, INC. SanBio Company Limited Wanbishi Archives Co., Ltd. SANKEN SETSUBI KOGYO CO.,LTD. Yokogawa Electric Corporation SANKI Engineering Co., Ltd. ZENOAQ RESOURCE CO., LTD. SANPLATEC CORP. ZIMMER BIOMET Special Members Special Members Central Institute for Experimental Animals Japan Blood Products Organization Foundation for Biomedical Research and Innovation at Kobe Japan Food Research Laboratories Supporting Members Supporting Members AIR LIQUIDE Kogyo Gas Ltd. Kondoh Industries, Ltd. ANTI-AGEING Co,.Ltd. KURARAY CO., LTD. B.BRAUN AESCULAP JAPAN CO., LTD. Mitsui Chemicals, Inc. COREFRONT Corporation MUTOH CO., LTD. Corning International K.K. Nikon CeLL innovation Co., Ltd. COSMO BIO CO., LTD. NIPPON SHOKUBAI Co.,LTD Cytori Therapeutics K.K. Nobelpharma Co., Ltd. Daewoong Pharmaceutical Co., Ltd. PAREXEL International Inc. EELS(Edogawa Evolutionary Laboratory of Science) RICOH COMPANY, LTD. ERNST & YOUNG SHINNIHON LLC SCREEN Holdings Co., Ltd. Evonik Japan Co., Ltd. SEKISUI SEIKEI, LTD. FUJISOFT Tissue Engineering Co., Ltd. SHIN NIPPON AIR TECHNOLOGIES CO., LTD. Hitachi Plant Services Co., Ltd. SunFlare Co., Ltd. Human Life CORD Japan Inc. Takasago Thermal Engineering Co., Ltd. intellim Corporation TEC Project Services Corporation JTB Communication Design, Inc. Toshiba Corporation KAN Research Institute, Inc. Individual Members Individual Members Fuyuhiko Mori Mime Egami Fumiaki Hirata Naoki Watanabe Kenji Maekawa Rika Tanaka Masato Deguchi Zen-ichi Mohri Honorary Member Ｔoichi Ｔakenaka Yuzo Toda 2.
Load more

Recommended publications
  • Research Paper Inter-Industry Innovations in Terms of Electric Mobility: Should Firms Take a Look Outside Their Industry?
    Inter-industry innovations in terms of electric mobility: Should firms take a look outside their industry? Research Paper Inter-industry innovations in terms of electric mobility: Should firms take a look outside their industry? Stephan von Delft* * University of Münster, Institute of Business Administration at the Department of Chemistry and Pharmacy, Leonardo-Campus 1, 48149 Münster, Germany, [email protected] The beginning electrification of the automotive powertrain is supposed to have a major impact on the automobile value chain - reshaping it significantly and brin- ging up new alliances, business models and knowledge bases. Such a transforma- tion of the value chain might fade boundaries between hitherto distinct knowled- ge bases, technologies, or industries. Over the past decades, the blurring of indus- try boundaries – the phenomenon of industry convergence – has gained attenti- on from researchers and practitioners. The anticipation of a convergence process plays an important role for strategic and innovation management decisions, e.g. for new business development, mergers and acquisitions or strategic partnerships. However, despite the relevance of convergence, it is often challenging for incum- bent firms to (1) foresee such a transformation of their environment, and (2) res- pond strategically to it. Hence, this study presents a tool to anticipate convergen- ce and strategic implications are discussed. 1 Introduction stitute rules of conducting business” (Hacklin et al., 2009, p. 723). Firms facing such a situation, thus Technological change is known as a key driver have to adapt to new knowledge bases and new of economic growth and prosperity (Schumpeter, technologies which do not belong to their former 1947; Abernathy and Utterback, 1978; Kondratieff, core competences or their traditional expertise 1979).
    [Show full text]
  • Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan
    Haematologica HAEMATOL/2018/194894 Version 3 Haematologica HAEMATOL/2018/194894 Version 3 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, and Hisashi Wakita Disclosures: 1. This study was supported by research funding from Novartis Pharmaceuticals to N.T. 2. N.T reports grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; K.N reports grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; C.N reports personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; M.T. reports personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M reports grants from Kyowa Hakko Kirin Co.
    [Show full text]
  • OCTOBER 2020 PTAB Public Hearing Schedule
    OCTOBER 2020 PTAB Public Hearing Schedule Proceeding No. Serial No. PARTY Date Time 2020-004197 16043641 BIOGEN MA INC Thursday, October 1, 2020 9:00 AM (EDT) ALLERGAN PHARMACEUTICALS 2020-002635 13907447 Thursday, October 1, 2020 9:00 AM (EDT) INTERNATIONAL LIMITED 2020-002276 13612925 BAYER AG (MONSANTO) Thursday, October 1, 2020 9:00 AM (EDT) 2020-002277 13612929 OTSUKA PHARMACEUTICAL CO., 2020-002304 14341306 Thursday, October 1, 2020 9:00 AM (EDT) LTD. 2020-002327 15893354 CELLECTIS Thursday, October 1, 2020 9:00 AM (EDT) 2020-000258 15163285 POLY GROUP LLC Thursday, October 1, 2020 9:00 AM (PDT) 2020-000640 15414456 DISCERNDX INC. Thursday, October 1, 2020 9:00 AM (PDT) 2020-000934 13982470 DENOVO BIOMARKERS INC. Thursday, October 1, 2020 9:00 AM (PDT) THE BOARD OF TRUSTEES OF THE 2020-001247 15175848 LELAND STANFORD JUNIOR Thursday, October 1, 2020 9:00 AM (PDT) UNIVERSITY EDWARDS LIFESCIENCES 2020-001487 14563866 Thursday, October 1, 2020 9:00 AM (PDT) CORPORATION IKEDA FOOD RESEARCH COL LTD 2020-003630 16145178 Thursday, October 1, 2020 1:00 PM (EDT) and PHC CORPORATION 2020-002049 13310632 ADARE PHARMACEUTICALS INC. Thursday, October 1, 2020 1:00 PM (EDT) 2020-000053 13135898 OLEG ILLICH EPSHTEIN Thursday, October 1, 2020 1:00 PM (EDT) 2020-001829 15008646 MERZ PHARMA GMBH & CO. KGAA Thursday, October 1, 2020 1:00 PM (EDT) 2020-002360 15407037 IONIS PHARMACEUTICALS INC. Thursday, October 1, 2020 1:00 PM (EDT) 2020-002113 13729631 L'OREAL Thursday, October 1, 2020 1:00 PM (EDT) 2019-003658 13576565 QUNZHU LI and LI LI Thursday, October 1, 2020 1:00 PM (EDT) 2020-000322 14136660 CYTEC INDUSTRIES INC.
    [Show full text]
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
    [Show full text]
  • Published on July 21, 2021 1. Changes in Constituents 2
    Results of the Periodic Review and Component Stocks of Tokyo Stock Exchange Dividend Focus 100 Index (Effective July 30, 2021） Published on July 21, 2021 1. Changes in Constituents Addition（18） Deletion（18） CodeName Code Name 1414SHO-BOND Holdings Co.,Ltd. 1801 TAISEI CORPORATION 2154BeNext-Yumeshin Group Co. 1802 OBAYASHI CORPORATION 3191JOYFUL HONDA CO.,LTD. 1812 KAJIMA CORPORATION 4452Kao Corporation 2502 Asahi Group Holdings,Ltd. 5401NIPPON STEEL CORPORATION 4004 Showa Denko K.K. 5713Sumitomo Metal Mining Co.,Ltd. 4183 Mitsui Chemicals,Inc. 5802Sumitomo Electric Industries,Ltd. 4204 Sekisui Chemical Co.,Ltd. 5851RYOBI LIMITED 4324 DENTSU GROUP INC. 6028TechnoPro Holdings,Inc. 4768 OTSUKA CORPORATION 6502TOSHIBA CORPORATION 4927 POLA ORBIS HOLDINGS INC. 6503Mitsubishi Electric Corporation 5105 Toyo Tire Corporation 6988NITTO DENKO CORPORATION 5301 TOKAI CARBON CO.,LTD. 7011Mitsubishi Heavy Industries,Ltd. 6269 MODEC,INC. 7202ISUZU MOTORS LIMITED 6448 BROTHER INDUSTRIES,LTD. 7267HONDA MOTOR CO.,LTD. 6501 Hitachi,Ltd. 7956PIGEON CORPORATION 7270 SUBARU CORPORATION 9062NIPPON EXPRESS CO.,LTD. 8015 TOYOTA TSUSHO CORPORATION 9101Nippon Yusen Kabushiki Kaisha 8473 SBI Holdings,Inc. 2.Dividend yield (estimated) 3.50% 3. Constituent Issues (sort by local code) No. local code name 1 1414 SHO-BOND Holdings Co.,Ltd. 2 1605 INPEX CORPORATION 3 1878 DAITO TRUST CONSTRUCTION CO.,LTD. 4 1911 Sumitomo Forestry Co.,Ltd. 5 1925 DAIWA HOUSE INDUSTRY CO.,LTD. 6 1954 Nippon Koei Co.,Ltd. 7 2154 BeNext-Yumeshin Group Co. 8 2503 Kirin Holdings Company,Limited 9 2579 Coca-Cola Bottlers Japan Holdings Inc. 10 2914 JAPAN TOBACCO INC. 11 3003 Hulic Co.,Ltd. 12 3105 Nisshinbo Holdings Inc. 13 3191 JOYFUL HONDA CO.,LTD.
    [Show full text]
  • Kuraray/ Glsv Business
    EN Case No COMP/M.7115 - KURARAY/ GLSV BUSINESS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) in conjunction with Art 6(2) Date: 29/04/2014 In electronic form on the EUR-Lex website under document number 32014M7115 Office for Publications of the European Union L-2985 Luxembourg EUROPEAN COMMISSION Brussels, 29.4.2014 C(2014) 2946 final In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 PUBLIC VERSION concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a MERGER PROCEDURE general description. To the notifying party: Dear Sir/Madam, Subject: Case M.7115 – Kuraray/ GLSV Business Commission decision pursuant to Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation No 139/20041 1. On 6 March 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ("the Merger Regulation") by which Kuraray Co., Ltd. ("Kuraray", Japan) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the Glass Laminating Solutions/Vinyls Business ("GLSV") of E. I. du Pont de Nemours and Company ("DuPont", USA), by way of purchase of assets. Kuraray and GLSV are hereinafter collectively referred to as "the Parties" while Kuraray individually is referred to as "Notifying Party". I. THE PARTIES AND THE OPERATION 2.
    [Show full text]
  • OSB Participant List by Research Area
    OSB Participant List by Research Area Contact Centers (CC) • AARP • Air Products and • American Drug Stores Chemicals • AAA • ABB • American Electric Power • Airbus • Accor • Abbott • American Express • Alcatel Lucent • American Electric Power • Abengoa • American International • Alcoa Group • American International • Abu Dhabi National Group Energy Company • Alcon • American Stores Company • Austin Energy • ACC Limited • Alfa • American Water • Bank of America • Access Insurance Holdings • Algonquin Power & • Amgen Utilities • Blue Cross Blue Shield • Accord Holdings • AMIL • ALH Group • Charles Schwab & • ACE • AmInvestment Bank Company • Alitalia • Acea • AMR • Citigroup • ALK Abello • Acer • Amssi • Citizens Gas • Alkermes • Acxiom • Amtran Logistics • Clarke American • Allergan • Adelaide Clinic Holdings • Andrew Corporation • CPS Energy • Alliance & Leicester • Adidas • Anglian Water Services • Direct Energy • Alliance Boots • Advance Food Company • Anritsu • Federal Reserve Bank of • Alliant Techsystems Minneapolis • Advance Publications • Anschutz • Allianz • John Deere • Advanced Coating • Apache • Allied Irish Banks • Technologies Louisville Water Company • Apex Equity Holdings • Advanced Semiconductor • Allstate Insurance • Manila Electric Company Engineering Company • Apple • • • Mellon Financial Adventist Health System Ally Financial • Arcadia Housing • • • MetLife Aegon Alon USA Energy • Arcos Dorados Holdings • • • Morgan Stanley AEON AlpTransit Gotthard • Ardent Health Services • • • NetBank Aera Energy Alstom • Argos •
    [Show full text]
  • Product Japan : Food Processing Sector - Health and Functional Foods Company Profiles
    Foreign Agricultural Service GAIN Report Global Agriculture Information Network Approved by: Date: 07/23/99 Sarah D. Hanson GAIN Report #JA9087 U.S. Embassy Market Brief - Product Japan : Food Processing Sector - Health and Functional Foods Company Profiles This report was prepared by the USDA’s Foreign Agricultural Service for U.S. exporters of food and agricultural products. This information is in the public domain and may be reprinted without permission. Use of commercial or trade names does not imply approval nor constitute endorsement by USDA/FAS. Tokyo[JA1], JA GAIN Report #JA9087 Page 1 of 24 Company Name Amway Japan Product Sector(s) Health and Functional Food Address 1-8-1, Shimo-Meguro Number Of Employees 728 Meguro-ku, Tokyo 153-8686 Number of Factories Overseas Contact Phone Number 03-5434-8484 Fax Number 03-5434-4923 Email Web Page Address www.amway.co.jp/amway_japan/ Contact Person Masura Iwata Executive Driector, External Affairs and Public Relations Sales and Net Profits Main Suppliers Year Sales (Mil. \) Net Profits 1995 177,991 22,424 1996 212,195 25,130 1997 203,361 26,638 Key Products % of Total Company Profile and Strategies Home Care Products 9 Japanese corporation of nonstore sales operator Amway (US). Housewares 30 Registered sales personnel involved in direct sales of detergents, Personal Care 34 cosmetics, kitchenware and nutritional supplements. Nutritional Supplements 23 Others 4 Main Brands Triple X (vitamin and mineral supplement), Nutri Protein, Acerola C (vitamin supplement), Salmon-Omega 3, Hon-E-Cece, Ironics, Beta Carotene A, Wheat Germ E. Main Ingredients Vitamins, protein concentrates, iron concentrates, calcium concentrates, beta caroten, wheat germ.
    [Show full text]
  • Ranking of Stocks by Market Capitalization(As of End of Apr.2014) 1St Section
    Ranking of Stocks by Market Capitalization(As of End of Apr.2014) 1st Section Rank Code Issue Market Capitalization \100mil. 1 7203 TOYOTA MOTOR CORPORATION 190,191 2 9984 SoftBank Corp. 91,130 3 8306 Mitsubishi UFJ Financial Group,Inc. 76,769 4 9437 NTT DOCOMO,INC. 70,800 5 7267 HONDA MOTOR CO.,LTD. 61,226 6 8316 Sumitomo Mitsui Financial Group,Inc. 57,028 7 9433 KDDI CORPORATION 48,812 8 8411 Mizuho Financial Group,Inc. 48,527 9 2914 JAPAN TOBACCO INC. 44,746 10 6954 FANUC CORPORATION 44,069 11 7751 CANON INC. 42,880 12 9432 NIPPON TELEGRAPH AND TELEPHONE CORPORATION 41,418 13 6902 DENSO CORPORATION 41,126 14 7201 NISSAN MOTOR CO.,LTD. 39,646 15 4502 Takeda Pharmaceutical Company Limited 36,230 16 3382 Seven & I Holdings Co.,Ltd. 35,732 17 6501 Hitachi,Ltd. 35,139 18 9983 FAST RETAILING CO.,LTD. 33,699 19 8802 Mitsubishi Estate Company,Limited 32,173 20 8058 Mitsubishi Corporation 30,226 21 5108 BRIDGESTONE CORPORATION 29,759 22 9020 East Japan Railway Company 29,439 23 6752 Panasonic Corporation 27,449 24 8801 Mitsui Fudosan Co.,Ltd. 26,627 25 8031 MITSUI & CO.,LTD. 26,504 26 4503 Astellas Pharma Inc. 25,978 27 4063 Shin-Etsu Chemical Co.,Ltd. 25,917 28 9022 Central Japan Railway Company 25,832 29 5401 NIPPON STEEL & SUMITOMO METAL CORPORATION 25,468 30 4689 Yahoo Japan Corporation 25,285 31 6503 Mitsubishi Electric Corporation 24,971 32 6861 KEYENCE CORPORATION 23,946 33 8766 Tokio Marine Holdings,Inc.
    [Show full text]
  • FTSE Japan ESG Low Carbon Select
    2 FTSE Russell Publications 19 August 2021 FTSE Japan ESG Low Carbon Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country ABC-Mart 0.01 JAPAN Ebara 0.17 JAPAN JFE Holdings 0.04 JAPAN Acom 0.02 JAPAN Eisai 1.03 JAPAN JGC Corp 0.02 JAPAN Activia Properties 0.01 JAPAN Eneos Holdings 0.05 JAPAN JSR Corp 0.11 JAPAN Advance Residence Investment 0.01 JAPAN Ezaki Glico 0.01 JAPAN JTEKT 0.07 JAPAN Advantest Corp 0.53 JAPAN Fancl Corp 0.03 JAPAN Justsystems 0.01 JAPAN Aeon 0.61 JAPAN Fanuc 0.87 JAPAN Kagome 0.02 JAPAN AEON Financial Service 0.01 JAPAN Fast Retailing 3.13 JAPAN Kajima Corp 0.1 JAPAN Aeon Mall 0.01 JAPAN FP Corporation 0.04 JAPAN Kakaku.com Inc. 0.05 JAPAN AGC 0.06 JAPAN Fuji Electric 0.18 JAPAN Kaken Pharmaceutical 0.01 JAPAN Aica Kogyo 0.07 JAPAN Fuji Oil Holdings 0.01 JAPAN Kamigumi 0.01 JAPAN Ain Pharmaciez <0.005 JAPAN FUJIFILM Holdings 1.05 JAPAN Kaneka Corp 0.01 JAPAN Air Water 0.01 JAPAN Fujitsu 2.04 JAPAN Kansai Paint 0.05 JAPAN Aisin Seiki Co 0.31 JAPAN Fujitsu General 0.01 JAPAN Kao 1.38 JAPAN Ajinomoto Co 0.27 JAPAN Fukuoka Financial Group 0.01 JAPAN KDDI Corp 2.22 JAPAN Alfresa Holdings 0.01 JAPAN Fukuyama Transporting 0.01 JAPAN Keihan Holdings 0.02 JAPAN Alps Alpine 0.04 JAPAN Furukawa Electric 0.03 JAPAN Keikyu Corporation 0.02 JAPAN Amada 0.01 JAPAN Fuyo General Lease 0.08 JAPAN Keio Corp 0.04 JAPAN Amano Corp 0.01 JAPAN GLP J-REIT 0.02 JAPAN Keisei Electric Railway 0.03 JAPAN ANA Holdings 0.02 JAPAN GMO Internet 0.01 JAPAN Kenedix Office Investment Corporation 0.01 JAPAN Anritsu 0.15 JAPAN GMO Payment Gateway 0.01 JAPAN KEWPIE Corporation 0.03 JAPAN Aozora Bank 0.02 JAPAN Goldwin 0.01 JAPAN Keyence Corp 0.42 JAPAN As One 0.01 JAPAN GS Yuasa Corp 0.03 JAPAN Kikkoman 0.25 JAPAN Asahi Group Holdings 0.5 JAPAN GungHo Online Entertainment 0.01 JAPAN Kinden <0.005 JAPAN Asahi Intecc 0.01 JAPAN Gunma Bank 0.01 JAPAN Kintetsu 0.03 JAPAN Asahi Kasei Corporation 0.26 JAPAN H.U.
    [Show full text]
  • Factset-Top Ten-0521.Xlsm
    Pax International Sustainable Economy Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight ASML Holding NV 34,391,879.94 4.3 Roche Holding Ltd 28,162,840.25 3.5 Novo Nordisk A/S Class B 17,719,993.74 2.2 SAP SE 17,154,858.23 2.1 AstraZeneca PLC 15,759,939.73 2.0 Unilever PLC 13,234,315.16 1.7 Commonwealth Bank of Australia 13,046,820.57 1.6 L'Oreal SA 10,415,009.32 1.3 Schneider Electric SE 10,269,506.68 1.3 GlaxoSmithKline plc 9,942,271.59 1.2 Allianz SE 9,890,811.85 1.2 Hong Kong Exchanges & Clearing Ltd. 9,477,680.83 1.2 Lonza Group AG 9,369,993.95 1.2 RELX PLC 9,269,729.12 1.2 BNP Paribas SA Class A 8,824,299.39 1.1 Takeda Pharmaceutical Co. Ltd. 8,557,780.88 1.1 Air Liquide SA 8,445,618.28 1.1 KDDI Corporation 7,560,223.63 0.9 Recruit Holdings Co., Ltd. 7,424,282.72 0.9 HOYA CORPORATION 7,295,471.27 0.9 ABB Ltd. 7,293,350.84 0.9 BASF SE 7,257,816.71 0.9 Tokyo Electron Ltd. 7,049,583.59 0.9 Munich Reinsurance Company 7,019,776.96 0.9 ASSA ABLOY AB Class B 6,982,707.69 0.9 Vestas Wind Systems A/S 6,965,518.08 0.9 Merck KGaA 6,868,081.50 0.9 Iberdrola SA 6,581,084.07 0.8 Compagnie Generale des Etablissements Michelin SCA 6,555,056.14 0.8 Straumann Holding AG 6,480,282.66 0.8 Atlas Copco AB Class B 6,194,910.19 0.8 Deutsche Boerse AG 6,186,305.10 0.8 UPM-Kymmene Oyj 5,956,283.07 0.7 Deutsche Post AG 5,851,177.11 0.7 Enel SpA 5,808,234.13 0.7 AXA SA 5,790,969.55 0.7 Nintendo Co., Ltd.
    [Show full text]
  • Sumitomo Chemical 100 Years Sumitomo Chemical 100 Years Published: August 2014 Published by Sumitomo Chemical Co.,Ltd
    Sumitomo Chemical 100 Years Sumitomo Chemical 100 Years Published: August 2014 Published by Sumitomo Chemical Co.,Ltd. Production and editing : Sumitomo Chemical Co.,Ltd., Corporate History Editorial Office 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo, Japan Production assisted by Dai Nippon Printing Co.,Ltd. Printed in Japan by Dai Nippon Printing Co.,Ltd. CONTENTS Chairman’s Message President’s Message The Path to a Global Chemical Company 1. The History of Sumitomo 8 2. History of Sumitomo Fertilizer Works 10 3. Going from a Fertilizer Manufacturer to a Chemical Company 14 4. Moving into Fine Chemicals 16 5. Post-war Recovery 18 6. Moving into the Agricultural Chemicals Business 20 7. Growth of the Pharmaceuticals Sector 22 8. Entering the Field of Petrochemicals 24 9. Dealing with the Oil Crises 26 10. Rise and Decline of Aluminum Business 28 11. Construction of Singapore Petrochemical Complex 32 12. Separation of Pharmaceutical Business from Sumitomo Chemical and Inauguration 34 of Dainippon Sumitomo Pharma Co., Ltd. 13. Expansion of Agricultural Chemicals Business 36 14. IT-related Chemicals Sector Established and Business Grows 38 15. Progress of the Rabigh Project 40 16. Aiming to be a Truly Global Chemical Company 42 17. For a Better Tomorrow 46 Reports from Regional Headquarters 48 Report from Beijing by Sumitomo Chemical (China) Co., Ltd. 48 Report from Singapore by Sumitomo Chemical (Asia Pacific) Pte Ltd 50 Report from Brussels by Sumitomo Chemical Europe S.A./N.V. 52 Report from New York by Sumitomo Chemical America, Inc. 54 The Sumitomo Spirit and Sumitomo Chemical’s Business Philosophy 56 Recent Sales and Profits 57 Sumitomo Chemical Locations in Japan 58 Major Companies of Sumitomo Chemical Group: Japan 59 Major Companies of Sumitomo Chemical Group: International 60 Chronology of Sumitomo Chemical 62 Chairman’s Message In October 2015, Sumitomo Chemical will cele- triggered by the fall of Lehman Brothers and the sub- brate its 100 year anniversary.
    [Show full text]